Staburo supported an exploratory analysis of the mRNA-1273 Phase 1 Trial to assess the clinical utility of the quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay (ACOV2S). Geometric mean concentrations as well as seroconversion over time was assessed overall and by dose and age group.
Antibodies were detectable already at the first time point of assessment. All participants had seroconverted at the time point of the second assessment.
The paper was recently published in Frontiers in Immunology: https://doi.org/10.3389/fimmu.2021.798117
Staburo’s contribution is mentioned in the acknowledgements.
